Table 2.

Features and treatment of patients with recurrent thrombotic or obstetric events

Pt	Age first event (years)	APS type	Triple + aPL	First event	Initial treatment	Time to recurrence (months)	Recurrent event	AC prescribed at time of recurrence	Adherence to AC treatment
5	14	2°, Thr	Yes	Splenic infarctiona	LDA	7.6	Renal TMAb	LDA	Yes
8	17	2°, Thr	Yes	Myocardial infarctionb	Fondaparinux and LDA	80.5	Cardiac thrombusd	LDA; apixaban recently discontinued	Yes
11	16	1°, Thr	Yes	PE, lower extremity DVTc	Warfarin	59.0	Lower extremity DVTc	Warfarin	No (loss of health insurance)
13	16	2°, Thr	No	Lower extremity DVTc	Warfarin (planned for 3 months)	19.4	Lower extremity DVTd	None	-
						62.1	Lower extremity DVTd	Rivaroxaban	No (patient reported)
14	18	2°, Obs	No	HELLP, Pre-eclampsia, thrombotic vasculopathy of placenta and skind	LMWH – prophylactic dose	4.6	Early pregnancy lossd	LMWH – prophylactic dose	Yes
16	10	2°, Thr	No	CVA, renal infarctiond	LMWH	23.4	CVAd	LMWH	No (physician reported)
18	12	1°, Thr	Yes	Liver lesions with small-vessel thrombotic vasculopathy d	LMWH	3.0	PEd	LMWH	No (family reported)
19	15	1°, Thr	Yes	Lower extremity DVTc	LMWH transitioned to warfarin	36.8	Portal vein thrombosis d	Warfarin	No (physician reported)
						74.8	CVAd	Warfarin	No (physician reported)
20	17	1°, Thr	No	Lower extremity DVTc	LMWH	2.0	PEc	None (suspected medication interaction on LMWH)	-
						2.9	PEc	Warfarin (subtherapeutic) transitioning to LMWH	Yes
						4.0	PEd	LMWH	No (physician reported)
						11.6	PE with secondary pulmonary infarctiond	Fondaparinux and LDA	Yes

Pt Patient number, AC Anticoagulation, 1° Primary AOS, 2° Secondary APS, Obs Obstetric, Thr Thrombotic, LDA Low dose aspirin, TMA Thrombotic Microangiopathy, PE pulmonary embolism, DVT Deep Vein Thrombosis, HELLP Hemolysis, Elevated Liver enzymes, Low Platelet count syndrome, LMWH Low molecular weight heparin (enoxaparin), CVA cerebrovascular accident. ^a2000-2004, ^b2005-2009, ^c2010-2014, ^d2015-2020